Dr. Chadha is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
University of Chicago - Section of Dermatology
5841 S Maryland Ave, MC 6092
Chicago, IL 60637
Summary
- Dr. Angad Chadha is a dermatologist based in Chicago, IL. He completed his medical education at Northwestern University, followed by an internship at Ascension Illinois/Resurrection, and a dermatology residency where he also served as Chief Resident at Henry Ford Health. He currently serves as a Dermatologist and Assistant Professor at the University of Chicago Medical Center and is a Resident Physician at AMITA Health Resurrection Medical Center. Dr. Chadha has published several articles in renowned journals such as JAMA Dermatology and JAAD Case Reports.
Education & Training
Henry Ford Health/Henry Ford HospitalChief Residency, Dermatology, 2019 - 2020- Henry Ford Health/Henry Ford HospitalResidency, Dermatology, 2017 - 2020
Ascension Illinois/ResurrectionInternship, Transitional Year, 2016 - 2017
Northwestern University The Feinberg School of MedicineClass of 2016, MD
Northwestern UniversityBS, 2008 - 2012
Certifications & Licensure
IL State Medical License 2020 - 2026
MI State Medical License 2017 - 2019
American Board of Dermatology Dermatology
Publications & Presentations
PubMed
- Combined RET and MEK Inhibition as a Treatment forFusion-Positive NSCLC With AcquiredFusion: A Case Report.Jacobi B Hines, Benjamin C Bowar, Margaret Colleton, Lydia Chelala, Peng Wang
JTO Clinical and Research Reports. 2024-11-01 - Necrotizing Fasciitis? A Mimic Produced by an Unusual Presentation of Necrotizing Neutrophilic Dermatosis of the Hand: A Case Report.Hussein Abdul-Rassoul, Robert Hight, Angad Chadha, Jason Strelzow
JBJS Case Connector. 2023-07-01 - Systemic mastocytosis, in the context of a deleterious germlinevariant, treated with ripretinib.Sara Saheb Kashaf, Lucy A Godley, Angad Chadha, Jason B Waldinger
JAAD Case Reports. 2023-07-01
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
